Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from PharmaTher Holdings Ltd ( (TSE:PHRM) ) is now available.
PharmaTher Holdings Ltd has announced that it is on track to submit responses to the FDA regarding its ketamine drug, with an expected approval date in Q2-2025. The company plans to focus on commercialization efforts upon approval, targeting pharmaceutical wholesalers and distributors, while also collaborating with the Defense Health Agency and Veterans Health Administration for treatment-resistant conditions. The company is also laying groundwork for next-generation ketamine products and strategic clinical collaborations, which could significantly impact its market position and expand its therapeutic offerings.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd is a specialty pharmaceutical company that focuses on the development and commercialization of ketamine. The company aims to be a leading innovator in providing ketamine for addressing unmet medical needs, particularly in the areas of mental health, neurological, and pain disorders.
YTD Price Performance: -1.96%
Average Trading Volume: 362,673
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $13.22M
See more insights into PHRM stock on TipRanks’ Stock Analysis page.
